An affinity threshold for maximum efficacy in anti-PD-1 immunotherapy

Monoclonal antibodies targeting the programmed cell death protein 1 (PD-1) remain the most prevalent cancer immunotherapy both as a monotherapy and in combination with additional therapies. Despite the extensive success of anti-PD-1 monoclonal antibodies in the clinic, the experimental relationship...

Descripción completa

Detalles Bibliográficos
Autores principales: Cowles, Sarah C., Sheen, Allison, Santollani, Luciano, Lutz, Emi A., Lax, Brianna M., Palmeri, Joseph R., Freeman, Gordon J., Wittrup, K. Dane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354768/
https://www.ncbi.nlm.nih.gov/pubmed/35924382
http://dx.doi.org/10.1080/19420862.2022.2088454

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354768/
https://www.ncbi.nlm.nih.gov/pubmed/35924382
http://dx.doi.org/10.1080/19420862.2022.2088454

Ejemplares similares